Report: Endo to shutter R&D facility; Prosensa's DMD drugs earn orphan status; Zytoprotec raises 2M euros;

 @FierceBiotech: Genentech plucks rights to Afraxis drug assets in $187M deal. News | Follow @FierceBiotech

@JohnCFierce: Big Biotech throwing up state legislative roadblocks against biosimilars, from Pollack at the NYT. More | Follow @JohnCFierce

@RyanMFierce: Biotech billionaire Soon-Shiong unveils 'convergence' cancer drug startup... Why it's unique? Tech convergence. News | Follow @RyanMFierce

> Pharmalot reports that Endo--which sells the painkiller Opana--is closing an R&D facility in Long Island, axing 58 workers in the process. Story

> The Dutch biotech Prosensa won orphan drug status for all its Duchenne muscular dystrophy drugs in the U.S. and Europe. Release

> Austria's Zytoprotec raised €2 million from new investor Baxter Ventures, half of a planned €4 million Series A. Release

> Alnylam CEO John Maraganore says all of the company's $400 million in cash will be needed to back its pipeline efforts, with no plans to make an acquisition. Story

> Bausch + Lomb launched its Phase III program for latanoprostene bunod (previously known as BOL-303259-X and NCX 116, in-licensed from NicOx) for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. Release

Pharma News

@FiercePharma: Another Hospira recall: Electrolyte solution, after customer complained of mold. No reported injuries. More | Follow @FiercePharma

 @AlisonBFierce: DARPA produced 10 million H1N1 flu vaccine doses in a month. DARPA, Medicago are using tobacco plants instead of eggs. News | Follow @AlisonBFierce

@EricPFierce: Sartorius Stedim nabs top LEED designation for Puerto Rico plant that recycles AC condensation, uses solar power. Article | Follow @EricPFierce

> Fighting the $9B ghost of Lipitor past, Pfizer points to new drugs. Report

> Lilly sales and profits slide, but analysts expected worse. Article

Medical Device News

 @FierceMedDev: Medtronic launches large-scale neurostimulation trial. Item | Follow @FierceMedDev

 @MarkHFierce: BSX will cut as many as 1,000 additional jobs beyond 2011 restructuring--first disclosed in today's Q4 announcement. Release | Follow @MarkHFierce

 @DamianFierce: Next in the Bausch + Lomb saga: Either it's going for an IPO or this is a gambit to pressure buyers. News | Follow @DamianFierce

> Illumina soars on deCode sale, revenue jump. Report

> Blood Dx quickens search for breast cancer mutations. Story

Pharma Manufacturing News

> Hospira recalls product that may contain mold. News

> EU drugmakers say expect a year from OK to warehouse for new labels. Item

> FDA alleges 3 made millions off scam wholesaler. Story

> Sartorius PR plant first to get LEED's top rating. Article

Biotech Research News

> Addex approaches the clinic for rare dystonias. Article

> Orexo, AstraZeneca join forces against respiratory disease. Item

> Beta blockers could improve cancer treatment in stressed patients. News

> Stem cells help rats recover from stroke. Story

And Finally… A new Kaiser Permanente study finds that HIV patients suffer a higher rate of nonmelanoma skin cancer. Release


Suggested Articles

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline.

The World Health Organization has called out Big Pharma for its dearth of antibiotic innovation amid a growing threat of antimicrobial resistance.

The trial hit its primary endpoint by the time of an interim analysis, enabling Chi-Med to stop the study and start work on a filing for approval.